Robert Andrade - Fennec Pharmaceuticals Chief Officer
| FENC Stock | USD 6.06 0.05 0.83% |
Executive
Mr. Robert C. Andrade was appointed as Chief Financial Officer of the Company. He was Chief Financial Officer, Director of Adherex Technologies Inc. Mr. Andrade has served as a director of Adherex since July 2009 and Chief Financial Officer since September 2009. Mr. Andrade is a General Partner at DCML, a private investment partnership. Prior to DCML, Mr. Andrade was a portfolio manager for Millennium Partners from November 2005 until December 2007 and a securities analyst for Caxton Associates from March 2003 until November 2005. Prior to Caxton Associates LLC, Mr. Andrade was a private equity associate at Trimaran Capital Partners and an investment banking analyst at Bear Stearns since 2015.
| Age | 49 |
| Tenure | 9 years |
| Address | 68 TW Alexander Drive, Research Triangle Park, NC, United States, 27709 |
| Phone | 919 636 4530 |
| Web | https://www.fennecpharma.com |
Latest Insider Transactions
Andrade graduated from University of Southern California, where he earned a Masters of Arts degree and Bachelor of Arts degree in economics.Robert Andrade Latest Insider Activity
Tracking and analyzing the buying and selling activities of Robert Andrade against Fennec Pharmaceuticals stock is an integral part of due diligence when investing in Fennec Pharmaceuticals. Robert Andrade insider activity provides valuable insight into whether Fennec Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Fennec Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Fennec Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Robert Andrade over a week ago Acquisition by Robert Andrade of 15816 shares of Fennec Pharmaceuticals at 2.45 subject to Rule 16b-3 | ||
Robert Andrade over a month ago Acquisition by Robert Andrade of 1042 shares of Fennec Pharmaceuticals subject to Rule 16b-3 | ||
Robert Andrade over three months ago Acquisition by Robert Andrade of 1042 shares of Fennec Pharmaceuticals subject to Rule 16b-3 | ||
Robert Andrade over three months ago Acquisition by Robert Andrade of 37500 shares of Fennec Pharmaceuticals subject to Rule 16b-3 |
Fennec Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.027 % which means that it generated a profit of $0.027 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.0559) %, meaning that it created substantial loss on money invested by shareholders. Fennec Pharmaceuticals' management efficiency ratios could be used to measure how well Fennec Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 1.45, whereas Return On Tangible Assets are forecasted to decline to (0.63). At present, Fennec Pharmaceuticals' Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 1.21, whereas Total Assets are forecasted to decline to about 16.1 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| George Papandreou | Orchestra BioMed Holdings | 59 | |
| Rahul Kaushik | Disc Medicine | N/A | |
| Cate McCanless | Harmony Biosciences Holdings | N/A | |
| Srikanth Venkatraman | Disc Medicine | N/A | |
| Marinus Verwijs | Aerovate Therapeutics | 48 | |
| BSc MD | Aerovate Therapeutics | N/A | |
| Jean Franchi | Disc Medicine | 58 | |
| Valdas Jurkauskas | Ikena Oncology | N/A | |
| Gopi MBA | Larimar Therapeutics | 53 | |
| Sr DO | Larimar Therapeutics | 63 | |
| Juan Lorenzo | Orchestra BioMed Holdings | N/A | |
| Susan Fischer | Aerovate Therapeutics | N/A | |
| James Pennington | Janux Therapeutics | N/A | |
| Naseem MD | Olema Pharmaceuticals | 51 | |
| Daniel Steiner | Molecular Partners AG | N/A | |
| Bob Lally | Ikena Oncology | N/A | |
| Moriarty ESQ | Olema Pharmaceuticals | 56 | |
| Samantha Vuksanic | Ikena Oncology | N/A | |
| MS MD | Harmony Biosciences Holdings | N/A | |
| Sanjeev Khindri | Aerovate Therapeutics | N/A | |
| Tricia Glover | Harmony Biosciences Holdings | N/A | |
Management Performance
| Return On Equity | -10.06 | ||||
| Return On Asset | 0.027 |
Fennec Pharmaceuticals Leadership Team
Elected by the shareholders, the Fennec Pharmaceuticals' board of directors comprises two types of representatives: Fennec Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Fennec. The board's role is to monitor Fennec Pharmaceuticals' management team and ensure that shareholders' interests are well served. Fennec Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Fennec Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rostislav Raykov, CEO, Director | ||
| Mark Meier, VP Commercial | ||
| Christiana MBA, Chief Officer | ||
| Mark Gowland, Controller | ||
| Terry Evans, Chief Officer | ||
| Robert Andrade, Chief Officer | ||
| Dr MS, Chief Officer | ||
| Lei Fang, President Inc | ||
| Anne McKay, Regulatory Consultant | ||
| Alexander MS, Consultant | ||
| Adrian Haigh, Independent Director |
Fennec Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Fennec Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10.06 | ||||
| Return On Asset | 0.027 | ||||
| Profit Margin | (0.02) % | ||||
| Operating Margin | (0.75) % | ||||
| Current Valuation | 158.03 M | ||||
| Shares Outstanding | 27.43 M | ||||
| Shares Owned By Insiders | 16.22 % | ||||
| Shares Owned By Institutions | 54.73 % | ||||
| Number Of Shares Shorted | 1.87 M | ||||
| Price To Earning | (3.82) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Fennec Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fennec Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fennec Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fennec Pharmaceuticals Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fennec Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Fennec Stock refer to our How to Trade Fennec Stock guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fennec Pharmaceuticals. If investors know Fennec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fennec Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.04) | Revenue Per Share 1.814 | Quarterly Revenue Growth 0.07 | Return On Assets 0.027 | Return On Equity (10.06) |
The market value of Fennec Pharmaceuticals is measured differently than its book value, which is the value of Fennec that is recorded on the company's balance sheet. Investors also form their own opinion of Fennec Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Fennec Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fennec Pharmaceuticals' market value can be influenced by many factors that don't directly affect Fennec Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fennec Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fennec Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fennec Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.